{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:07:47Z","timestamp":1788746867877,"version":"build-2803163510"},"reference-count":99,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the modern era of cardiovascular medicine, clinicians and researchers stand at a pivotal crossroads between the paradigms of evidence-based medicine (EBM) and personalized medicine (PM). This tension is particularly palpable in the management of heart failure (HF) and inherited cardiomyopathies, heterogeneous conditions with complex pathophysiology and variable individual trajectories. While EBM has shaped practice through robust clinical trials and guideline-directed therapies, PM challenges us to consider the uniqueness of the patient beyond population averages. This dilemma is clear when considering that EBM is extensive and robust in the field of HF, instead, high-quality evidence remains relatively scarce for inherited cardiomyopathies, which may often result in HF, further highlighting the critical role of PM in this domain. The divergence underscores a critical epistemological and practical issue: how can clinicians reconcile the generalizability of EBM with the specificity demanded by PM? This review critically examines the philosophical foundations and clinical implications of this paradigm interplay, with a focus on HF and cardiomyopathies. It explores emerging strategies that aim to bridge the gap between standardized care and individualized management. Finally, it proposes a conceptual framework for harmonizing EBM and PM, advocating for a dynamic, context-sensitive approach that leverages the strengths of both paradigms to optimize patient outcomes in an era of personalized cardiovascular care.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag596","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:20:18Z","timestamp":1784546418000},"source":"Crossref","is-referenced-by-count":0,"title":["Reconciling evidence-based and personalized medicine: perspectives in heart failure and cardiomyopathies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7040-2832","authenticated-orcid":false,"given":"Gherardo","family":"Finocchiaro","sequence":"first","affiliation":[{"name":"Cardiovascular Clinical Academic Group City St George\u2019s, University of London, and St George\u2019s Hospital NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-2934","authenticated-orcid":false,"given":"Maria","family":"Perotto","sequence":"additional","affiliation":[{"name":"University Clinical Department of Medical, Surgical and Health Sciences, University of Trieste , Trieste ,","place":["Italy"]},{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (Member of the European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart) , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-3131","authenticated-orcid":false,"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[{"name":"University Clinical Department of Medical, Surgical and Health Sciences, University of Trieste , Trieste ,","place":["Italy"]},{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (Member of the European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart) , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-538X","authenticated-orcid":false,"given":"Thomas F","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"Center for Molecular Cardiology, University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Heart Division, Royal Brompton & Harefield Hospitals GSTT and Cardiovascular Academic Group, King\u2019s College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-2460","authenticated-orcid":false,"given":"William J","family":"McKenna","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-8478","authenticated-orcid":false,"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"University Clinical Department of Medical, Surgical and Health Sciences, University of Trieste , Trieste ,","place":["Italy"]},{"name":"Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (Member of the European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart) , Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090621235917700_ehag596-B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"2026090621235917700_ehag596-B2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B3","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B4","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","article-title":"Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches","volume":"402","author":"Heymans","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"2026090621235917700_ehag596-B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3725","article-title":"Evidence based medicine: a movement in crisis?","volume":"348","author":"Greenhalgh","year":"2014","journal-title":"BMJ"},{"key":"2026090621235917700_ehag596-B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6963-2-3","article-title":"What kind of evidence is it that evidence-based medicine advocates want health care providers and consumers to pay attention to?","volume":"2","author":"Haynes","year":"2002","journal-title":"BMC Health Serv Res"},{"key":"2026090621235917700_ehag596-B8","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1093\/eurheartj\/ehae465","article-title":"Artificial intelligence in cardiovascular medicine: clinical applications","volume":"45","author":"L\u00fcscher","year":"2024","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Streptomycin treatment of pulmonary tuberculosis","volume":"2","author":"Group BMJP","year":"1948","journal-title":"BMJ"},{"key":"2026090621235917700_ehag596-B11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1001\/jama.1997.03550200063033","article-title":"Evidence-based disease management","volume":"278","author":"Ellrodt","year":"1997","journal-title":"JAMA"},{"key":"2026090621235917700_ehag596-B12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","article-title":"Progress in evidence-based medicine: a quarter century on","volume":"390","author":"Djulbegovic","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"2026090621235917700_ehag596-B13","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1001\/jama.1993.03510170086037","article-title":"Users\u2019 guides to the medical literature","volume":"270","author":"Guyatt","year":"1993","journal-title":"JAMA"},{"key":"2026090621235917700_ehag596-B14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1353\/pbm.2005.0098","article-title":"Looking for rules in a world of exceptions: reflections on evidence-based practice","volume":"48","author":"Upshur","year":"2005","journal-title":"Perspect Biol Med"},{"key":"2026090621235917700_ehag596-B15","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1001\/jama.2012.13444","article-title":"Empirical evaluation of very large treatment effects of medical interventions","volume":"308","author":"Pereira","year":"2012","journal-title":"JAMA"},{"key":"2026090621235917700_ehag596-B16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"2026090621235917700_ehag596-B17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions","volume":"325","author":"The SOLVD investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B19","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS)","volume":"90","year":"1994","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B21","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038644","article-title":"Heart disease mortality in the United States, 1970 to 2022","volume":"14","author":"King","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026090621235917700_ehag596-B24","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/eurheartj\/ehaf009","article-title":"2024 revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention","volume":"46","author":"J\u00fcni","year":"2025","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/eurheartj\/ehx194","article-title":"Sudden cardiac death","volume":"38","author":"Finocchiaro","year":"2017","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","article-title":"A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation","volume":"62","author":"Geisterfer-Lowrance","year":"1990","journal-title":"Cell"},{"key":"2026090621235917700_ehag596-B28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM198705073161904","article-title":"X-linked dilated cardiomyopathy","volume":"316","author":"Berko","year":"1987","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B29","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1161\/01.CIR.87.6.1854","article-title":"X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus","volume":"87","author":"Towbin","year":"1993","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B30","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)02379-5","article-title":"Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease)","volume":"355","author":"McKoy","year":"2000","journal-title":"Lancet"},{"key":"2026090621235917700_ehag596-B31","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jacc.2016.08.058","article-title":"Long-term arrhythmic and nonarrhythmic outcomes of lamin A\/C mutation carriers","volume":"68","author":"Kumar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026090621235917700_ehag596-B32","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1093\/eurheartj\/ehab294","article-title":"Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction","volume":"42","author":"Verstraelen","year":"2021","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B33","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.119.044934","article-title":"Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy","volume":"141","author":"Smith","year":"2020","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamacardio.2024.5543","article-title":"Arrhythmic risk stratification of carriers of filamin C truncating variants","volume":"10","author":"Gigli","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026090621235917700_ehag596-B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005700","article-title":"Pathogenic RBM20-variants are associated with a severe disease expression in male patients with dilated cardiomyopathy","volume":"12","author":"Hey","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026090621235917700_ehag596-B36","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1001\/jama.2015.3595","article-title":"The precision medicine initiative: a new national effort","volume":"313","author":"Ashley","year":"2015","journal-title":"JAMA"},{"key":"2026090621235917700_ehag596-B37","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1093\/eurheartj\/ehae519","article-title":"Clinical trials in-a-dish for cardiovascular medicine","volume":"45","author":"Wu","year":"2024","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B38","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/europace\/euac030","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases","volume":"24","author":"Wilde","year":"2022","journal-title":"Europace"},{"key":"2026090621235917700_ehag596-B39","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B40","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/eurheartj\/ehq025","article-title":"Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"31","author":"Marcus","year":"2010","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B41","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/j.jacc.2022.08.804","article-title":"Prognostic prediction of genotype vs phenotype in genetic cardiomyopathies","volume":"80","author":"Paldino","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026090621235917700_ehag596-B42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jacc.2011.08.078","article-title":"Risk factors for malignant ventricular arrhythmias in lamin A\/C mutation carriers","volume":"59","author":"van Rijsingen","year":"2012","journal-title":"JACC"},{"key":"2026090621235917700_ehag596-B43","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jchf.2023.09.015","article-title":"Applications of gene therapy in cardiomyopathies","volume":"12","author":"Argiro","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026090621235917700_ehag596-B45","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.114.009761","article-title":"Personalized cardiovascular medicine today","volume":"132","author":"Blaus","year":"2015","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026090621235917700_ehag596-B47","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"2026090621235917700_ehag596-B48","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026090621235917700_ehag596-B49","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/ejhf.2378","article-title":"Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026090621235917700_ehag596-B50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/HCO.0000000000000491","article-title":"Machine learning in heart failure: ready for prime time","volume":"33","author":"Awan","year":"2018","journal-title":"Curr Opin Cardiol"},{"key":"2026090621235917700_ehag596-B52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41569-024-01074-2","article-title":"Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine","volume":"22","author":"Gigli","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"2026090621235917700_ehag596-B53","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ejhf.3168","article-title":"Role of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy","volume":"26","author":"Setti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026090621235917700_ehag596-B54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cardfail.2018.03.004","article-title":"Genetic evaluation of cardiomyopathy\u2014a Heart Failure Society of America practice guideline","volume":"24","author":"Hershberger","year":"2018","journal-title":"J Card Fail"},{"key":"2026090621235917700_ehag596-B55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11886-025-02195-x","article-title":"Contemporary insights into LMNA cardiomyopathy","volume":"27","author":"Balakrishnan","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"2026090621235917700_ehag596-B56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006832","article-title":"Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene","volume":"13","author":"Akhtar","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026090621235917700_ehag596-B57","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","article-title":"Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction","volume":"135","author":"Halliday","year":"2017","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B58","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jacc.2022.07.023","article-title":"Natural history of MYH7-related dilated cardiomyopathy","volume":"80","author":"de Frutos","year":"2022","journal-title":"JACC"},{"key":"2026090621235917700_ehag596-B59","doi-asserted-by":"publisher","first-page":"10716","DOI":"10.1038\/s41598-025-95409-9","article-title":"Age at onset and clinical course of RBM20-mediated cardiomyopathy","volume":"15","author":"Garmany","year":"2025","journal-title":"Sci Rep"},{"key":"2026090621235917700_ehag596-B60","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacep.2024.02.031","article-title":"Phenotype and clinical outcomes in desmin-related arrhythmogenic cardiomyopathy","volume":"10","author":"Bermudez-Jimenez","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"2026090621235917700_ehag596-B61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003704","article-title":"Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population","volume":"15","author":"Bourfiss","year":"2022","journal-title":"Circ Genomic Precis Med"},{"key":"2026090621235917700_ehag596-B62","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/ehf2.14490","article-title":"Contribution of rare genetic variants to heart failure and cardiomyopathy in the UK Biobank","volume":"10","author":"Z\u00f6ller","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026090621235917700_ehag596-B63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCRESAHA.123.323200","article-title":"Myocardial recovery in recent onset dilated cardiomyopathy: role of CDCP1 and cardiac fibrosis","volume":"133","author":"Liu","year":"2023","journal-title":"Circ Res"},{"key":"2026090621235917700_ehag596-B64","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"2026090621235917700_ehag596-B65","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011548","article-title":"REALM-DCM: a phase 3, multinational, randomized, placebo-controlled trial of ARRY-371797 in patients with symptomatic LMNA-related dilated cardiomyopathy","volume":"17","author":"Garcia-Pavia","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026090621235917700_ehag596-B66","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.118.037230","article-title":"Sudden death and left ventricular involvement in arrhythmogenic cardiomyopathy","volume":"139","author":"Miles","year":"2019","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B67","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.jacc.2016.02.062","article-title":"Etiology of sudden death in sports: insights from a United Kingdom regional registry","volume":"67","author":"Finocchiaro","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026090621235917700_ehag596-B68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJMra1509267","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"376","author":"Corrado","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B69","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s10554-022-02684-y","article-title":"Arrhythmogenic cardiomyopathy and differential diagnosis with physiological right ventricular remodelling in athletes using cardiovascular magnetic resonance","volume":"38","author":"Moccia","year":"2022","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026090621235917700_ehag596-B70","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cjca.2020.12.013","article-title":"Preventing sudden death in arrhythmogenic cardiomyopathy: careful family and genetic evaluation key to appropriate diagnosis and management","volume":"37","author":"Ortiz-Genga","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026090621235917700_ehag596-B71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.008509","article-title":"Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: a multinational collaboration","volume":"14","author":"Cadrin-Tourigny","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026090621235917700_ehag596-B72","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.jacep.2025.08.026","article-title":"Arrhythmogenic cardiomyopathy or \u201cathlete\u2019s heart\u201d?","volume":"11","author":"Minopoli","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"2026090621235917700_ehag596-B73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-025-00643-0","article-title":"Hypertrophic cardiomyopathy","volume":"11","author":"Argir\u00f2","year":"2025","journal-title":"Nat Rev Dis Primer"},{"key":"2026090621235917700_ehag596-B74","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cjca.2024.01.011","article-title":"Emerging themes in genetics of hypertrophic cardiomyopathy: current Status and clinical application","volume":"40","author":"Garc\u00eda-Hern\u00e1ndez","year":"2024","journal-title":"Can J Cardiol"},{"key":"2026090621235917700_ehag596-B75","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/hrt.63.5.287","article-title":"Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass","volume":"63","author":"McKenna","year":"1990","journal-title":"Br Heart J"},{"key":"2026090621235917700_ehag596-B76","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/europace\/euaa012","article-title":"Diagnostic yield of hypertrophic cardiomyopathy in first-degree relatives of decedents with idiopathic left ventricular hypertrophy","volume":"22","author":"Finocchiaro","year":"2020","journal-title":"Europace"},{"key":"2026090621235917700_ehag596-B77","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/heartjnl-2014-307205","article-title":"Phenotype and prognostic correlations of the converter region mutations affecting the \u03b2 myosin heavy chain","volume":"101","author":"Garc\u00eda-Giustiniani","year":"2015","journal-title":"Heart"},{"key":"2026090621235917700_ehag596-B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.01.024","article-title":"The p.Asn271Ile variant in the TNNT2 gene is associated with low-risk late-onset hypertrophic cardiomyopathy","volume":"13","author":"Larra\u00f1aga-Moreira","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026090621235917700_ehag596-B79","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/jmedgenet-2021-107774","article-title":"Cardiac myosin binding protein-C variants in paediatric-onset hypertrophic cardiomyopathy: natural history and clinical outcomes","volume":"59","author":"Field","year":"2022","journal-title":"J Med Genet"},{"key":"2026090621235917700_ehag596-B80","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"2026090621235917700_ehag596-B81","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B82","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/ehjcvp\/pvae040","article-title":"CYP2C19 genetic testing for mavacamten and ischaemic stroke treatment: what does the result mean for cardiovascular prescribers in the UK and Europe?","volume":"10","author":"Magavern","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026090621235917700_ehag596-B83","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.15420\/cfr.2024.33","article-title":"Heart failure management in cardiac amyloidosis: towards a paradigm shift","volume":"11","author":"Panichella","year":"2025","journal-title":"Card Fail Rev"},{"key":"2026090621235917700_ehag596-B84","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026090621235917700_ehag596-B85","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez","year":"2025","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B86","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/amiajnl-2014-002977","article-title":"Toward a science of learning systems: a research agenda for the high-functioning learning health system","volume":"22","author":"Friedman","year":"2015","journal-title":"J Am Med Inform Assoc"},{"key":"2026090621235917700_ehag596-B87","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/eurheartj\/ehaf041","article-title":"Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table","volume":"46","author":"Dimmeler","year":"2025","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B88","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1038\/s41467-025-57481-7","article-title":"AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models","volume":"16","author":"Greer-Short","year":"2025","journal-title":"Nat Commun"},{"key":"2026090621235917700_ehag596-B89","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","article-title":"Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Kyriakopoulou","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"2026090621235917700_ehag596-B90","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1161\/CIRCULATIONAHA.122.061335","article-title":"Genome-wide CRISPR screen identifies an NF2-adherens junction mechanistic dependency for cardiac lineage","volume":"149","author":"Lee","year":"2024","journal-title":"Circulation"},{"key":"2026090621235917700_ehag596-B91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026090621235917700_ehag596-B92","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa2415539","article-title":"Mitochondrial donation and preimplantation genetic testing for mtDNA disease","volume":"393","author":"Hyslop","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090621235917700_ehag596-B93","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.adh0073","article-title":"Assisted reproductive technologies at the nexus of fertility treatment and disease prevention","volume":"380","author":"Herbert","year":"2023","journal-title":"Science"},{"key":"2026090621235917700_ehag596-B94","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med"},{"key":"2026090621235917700_ehag596-B95","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"key":"2026090621235917700_ehag596-B96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/hast.614","article-title":"From \u201cpersonalized\u201d to \u201cprecision\u201d medicine: the ethical and social implications of rhetorical reform in genomic medicine","volume":"46","author":"Juengst","year":"2016","journal-title":"Hastings Cent Rep"},{"key":"2026090621235917700_ehag596-B97","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1093\/eurheartj\/ehz644","article-title":"Lumpers and splitters: the bumpy road to precision medicine","volume":"40","author":"L\u00fcscher","year":"2019","journal-title":"Eur Heart J"},{"key":"2026090621235917700_ehag596-B98","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"2026090621235917700_ehag596-B99","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Angus","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag596\/70972690\/ehag596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag596\/70972690\/ehag596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:24:02Z","timestamp":1788744242000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag596\/8786399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":99,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag596","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"ehag596"}}